# Lead-212 VMT-alpha-NET

Source: https://nuclide.cc/drugs/pb-212-vmt-alpha-net/  
Nuclide record `pb-212-vmt-alpha-net` (Agent). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A drug that targets a marker on neuroendocrine tumour cells is being tested with two versions of a radioactive metal: one lets doctors see where the tumour is on a scan, and the other delivers a strong, short-range dose of radiation to kill the tumour cells.

## Summary

VMT-alpha-NET is Perspective Therapeutics' targeted alpha-particle therapy (TAT) programme for somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumours (NETs), pheochromocytoma/paraganglioma and meningioma. The same peptide is labelled with lead-203 for SPECT/CT imaging (used to plan a patient-specific kidney radiation-dose limit) and with the alpha-emitting isotope lead-212 for therapy.

The ongoing multicentre, open-label phase 1/2a trial (ClinicalTrials.gov NCT05636618) is a dose-escalation and dose-expansion study in up to about 300 adult, PRRT-naive patients with unresectable or metastatic SSTR2-positive NETs, bronchial NETs, pheochromocytoma/paraganglioma, or meningioma; dosing is by intravenous infusion roughly every 8 weeks. The FDA granted Fast Track designation in September 2022 for SSTR2-positive NETs regardless of prior treatment. A separate single-centre phase 1 study in PRRT-refractory patients (NCT06148636) is under way at the University of Iowa.

Interim data presented at ASCO-GI and AACR in 2026 (data cut-offs through April 2026) reported, across dose cohorts up to 64 patients, no dose-limiting toxicities, treatment-related discontinuations or grade 5 events, with grade 3+ adverse events in roughly a third of patients (mostly non-renal, non-myelosuppressive); in evaluable patients from the lower dose cohorts, 76% remained progression-free and alive, and an objective response rate of about 39-44% (RECIST v1.1) was reported in Cohort 2 (5 mCi per dose). VMT-alpha-NET has not received marketing authorisation in any jurisdiction; the programme is still determining its recommended phase 2 dose.

## Fields

- Kind: Agent
- Status: phase-2
- Last checked: 2026-09-22
- Also known as: 212Pb-VMT-alpha-NET; [212Pb]VMT-α-NET; 203Pb-VMT-alpha-NET (imaging analogue)
- Tags: alpha therapy; SSTR2; neuroendocrine tumours; lead-212; phase 1/2
- Code: VMT-alpha-NET
- Modality: alpha therapy
- Mechanism: A somatostatin receptor subtype 2 (SSTR2)-targeting peptide that can be radiolabelled either with lead-203 (a gamma emitter, for SPECT imaging and dosimetry planning) or with lead-212 (an in-vivo alpha-emitter generator via its decay chain), delivering high-linear-energy-transfer alpha radiation directly to SSTR2-expressing neuroendocrine tumour cells.
- Dosing: Intravenous infusion; Dose-escalation cohorts from 2.5 to 6.0 mCi per dose, approximately every 8 weeks, up to 4 administrations

## Sources

- Perspective Therapeutics: VMT-alpha-NET pipeline page: https://perspectivetherapeutics.com/pipeline/vmt-alpha-net
- ClinicalTrials.gov: NCT05636618: https://clinicaltrials.gov/study/NCT05636618
- Perspective Therapeutics: updated interim data at AACR 2026: https://www.globenewswire.com/news-release/2026/04/20/3276793/0/en/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-%CE%B1-net-in-its-ongoing-phase-1-2a-clinical-trial-at-the-2026-aacr-annual-meeting.html
- Perspective Therapeutics: first patient dosed press release, 2023: https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-first-patient-dosed-in-a-phase-1-study-of-212pbvmtnet-to-treat-refractory-or-relapsedneuroendocrine-tumors

## Connected records

- drugs: [177Lu-edotreotide](https://nuclide.cc/drugs/itm-11/), [212Pb-DOTAMTATE](https://nuclide.cc/drugs/alphamedix/), [Lead-212 PSV359](https://nuclide.cc/drugs/pb-212-psv359/), [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/)
- isotopes: [Lead-212](https://nuclide.cc/isotopes/pb-212/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/)
- technologies: [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- targets: [Somatostatin receptor 2](https://nuclide.cc/targets/sstr2/)
- companies: [Perspective Therapeutics](https://nuclide.cc/companies/perspective-therapeutics/)
- trials: [Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors](https://nuclide.cc/trials/nct05636618/)

---
JSON: https://nuclide.cc/api/v1/entities/pb-212-vmt-alpha-net.json